Figure 1.
Bazedoxifene inhibited the viability of cervical cancer cells in a dose-dependent manner. (A) SiHa, HeLa, and CaSki cells were treated with Bazedoxifene at the indicated concentrations in triplicate for 48 h and the MTT assay was performed to analyze cell viability (*, p < 0.5, **, p < 0.1, ***, p < 0.001 vs. control). (B) IC50 values were measured for each cell line following 48 h of treatment with various concentrations (1, 2, 4, 6, 8, and 10 μM) of Bazedoxifene. (C) Cervical cancer cells were treated with Bazedoxifene (1, 5, or 10 μM) in triplicate for 0, 24, 48, or 72 h, and the CCK assay was performed to analyze cell viability (*, p < 0.05 **, p < 0.01, ***, p < 0.001 vs. control). B: Bazedoxifene.